FRISS launches Insurance Is A Beautiful Thing campaign
1.9.2020 09:00:00 EEST | Business Wire | Press release
FRISS, the leading provider of AI-powered fraud and risk solutions for P&C insurance companies, known for its creative approach toward the insurance industry, launched an international campaign to regain a feeling of pride in the insurance industry. “Because insurance is anything but boring,” says FRISS.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200831005336/en/
Jeroen Morrenhof, CEO and Co-founder of FRISS: “We often recognize that people take insurance for granted. We want to remind everyone how important our industry is. The most incredible things in life can only be achieved thanks to insurance. Therefore we believe insurance really is a beautiful thing. And the world should know that, too.”
With its AI-powered fraud detection and risk assessment software, FRISS helps insurers provide a faster and more seamless experience for their customers. Morrenhof concludes: “I hope Insurance is a beautiful thing helps people grasp the beauty of our industry, and makes them realize how times continuously evolve, trends develop and customer expectations change. Carriers should change with them. It's time to find new ways of doing business. This is our wake-up call for insurers: Now is the time for digital transformation.”
According to research from the Insurance Information Institute, barely half of those surveyed have a positive perception of the insurance industry.
Yoram Elzas, Head of Creative at FRISS, says: “The lack of appreciation for the insurance industry is exactly why we are launching this campaign. We are putting the emotion back into insurance. Think of what brings you joy, personally. Without the right coverage, no one would be able to travel around the world, drive a car or buy their own house. And companies would never be able to hire staff, innovate or expand. Insurance allows us to take risks. Everyone in our industry should be proud of that.”
Insurance is a beautiful thing launched today. Feel the emotion and share the story: https://youtu.be/EqwKT11uEgo.
About FRISS
FRISS is a fast-growing insurtech with 100% focus on automated fraud detection and risk assessment for P&C insurance companies worldwide. Their AI-powered software solutions for underwriting, claims and special investigation units help 175+ insurers grow their business sustainably. Insurers go live within 4 months, realize up to 10 times ROI and see an 80% increase in straight-through processing of policy applications and claims. FRISS solutions help lower loss ratios, enable profitable portfolio growth and improve the overall customer experience. For more information, visit www.friss.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200831005336/en/
Contact information
FRISS PR & Communications
Ruud van Gerwen
Head of Global Marketing
ruud.van.gerwen@friss.com
+31 30 767 0352
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care28.4.2026 15:28:00 EEST | Press release
CTIBIOTECH Announces the CTIONCOTEST ™ Project to Revolutionize Cancer Research with 3D Bioprinted Microtumors, Backed by France 2030 and Bpifrance This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428242352/en/ The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the platform features three complexity levels: standard (cancer cells), intermediate (+fibroblasts), and advanced (+immune/endothelial cells) . A key breakthrough is its record cellular viability of
BMG and Concord Combine to Create World’s Leading Independent Music Company28.4.2026 15:11:00 EEST | Press release
BMG and Concord today announced a definitive agreement to combine their businesses, creating the leading independent music company in the world. Operating under the BMG name, the combined company will bring together two highly complementary businesses to establish a scaled, global company delivering superior service to artists, songwriters, and partners – firmly grounded in an independent, artist-first model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427537841/en/ Thomas Coesfeld and Bob Valentine, Courtesy of BMG and Concord The combination comes amid significant transformation in the global music market, where scale, global reach, and technology investment are increasingly critical to remain competitive. Together, BMG and Concord will form a fully integrated global music company spanning music publishing, recorded music, theatrical rights, and digital distribution. This increased scale will enable deeper investment
Masimo SET ® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study28.4.2026 15:00:00 EEST | Press release
Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET® pulse oximetry among critically ill neonates and demonstrating less than 1% overall statistical bias. Importantly, there were no clinically meaningful skin pigmentation-related discrepancies and no occult hypoxemic events among Black or Hispanic patients, and in only one Caucasian patient overall. The Neonatal Pulse Oximetry Accuracy and Disparities by Skin Pigmentation (NeoPODS) study findings were presented from the podium at the Pediatric Academic Society in Boston, MA on Monday, April 27th at 10 am EST by lead author Dr. Heather Siefkes on behalf of colleagues at the University of California, Davis and the University of Mississippi, Jackson, alongside online publication in the Journal of Pediatrics. As the authors noted, “[W]e found no evidence of clinically meaningful skin tone-related discrepancies, suggesting equitable monitoring performance for this device in this clinical setti
KAYTUS AI Compute Pod Wins 2026 iF Design Award and Red Dot Award, Setting a New Standard for AI Data Center28.4.2026 12:54:00 EEST | Press release
KAYTUS, a leading provider in AI infrastructure and liquid-cooling solutions, announced that its AI Compute Pod has received both the 2026 iF Design Award and Red Dot Award. This dual recognition not only stems from its outstanding performance in green, low-energy operation—achieving up to 130 kW cooling capacity per rack and a PUE as low as 1.1 through optimized thermal and power design—but also from its innovative approach to intelligent control and efficient O&M. The solution enables second-level synchronization between cooling and IT workloads, and leverages a dual-group control strategy to improve cooling energy efficiency by over 10%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428825343/en/ KAYTUS AI Compute Pod Wins 2026 iF Design Award and Red Dot Award, Setting a New Standard for AI Data Center Jury panels from both awards highlighted the AI Compute Pod's excellence in miniaturization, modularity, and intelli
Braskem to Showcase Sustainable Packaging Solutions at interpack 202628.4.2026 11:00:00 EEST | Press release
Braskem (B3: BRKM3, BRKM5, and BRKM6, NYSE: BAK, LATIBEX: XBRK) the largest polyolefins producer in the Americas, as well as a global market leader and pioneer producer of biopolymers on an industrial scale, will be at interpack 2026 in hall 9, booth A32, presenting packaging solutions made from bio-based, recycled and traditional polyolefins, enabling circular plastics, end-to-end. At interpack, Braskem will highlight I’m green™ bio‑based polyethylene grades specifically engineered for food‑contact applications, as well as Medcol V7040, a new grade for Healthcare and Hygiene. These innovations mark the first time Braskem has offered sustainably sourced sugarcane‑derived plastics for these segments. In an environment where packaging decisions are increasingly evaluated on both sustainability ambitions and business impact, Braskem positions itself as a materials partner offering multiple, complementary pathways toward circularity and lower emissions. Rather than a one‑size‑fits‑all solu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom